Thin and Ultrathin Bronchoscopy With Transbronchial Needle Aspiration and Radial Probe Endobronchial Ultrasound for Peripheral Pulmonary Lesions

Sponsor
Washington University School of Medicine (Other)
Overall Status
Recruiting
CT.gov ID
NCT04331587
Collaborator
Olympus (Industry)
80
1
1
48.3
1.7

Study Details

Study Description

Brief Summary

A limitation of current approaches to peripheral lesions may be the caliber of bronchoscope used to reach them. As peripheral airways taper further in size, the ability of the bronchoscopist to approximate peripheral lesions diminishes using conventionally sized bronchoscopes of 5 or 4mm in outer diameter. Because of this limitation, the bronchoscopist may be unable to cannulate peripheral airways that lead directly to targeted lesions, thereby significantly compromising the diagnostic yield of the procedure. Ultrathin bronchoscopy utilizing bronchoscopes of 3mm in outer diameter may allow bronchoscopists better access to the lung periphery, thereby allowing access to peripheral airways that may lead directly into targeted lesions, resulting in a concentric anatomical position, where diagnostic yields may be improved.

Condition or Disease Intervention/Treatment Phase
  • Device: BF-P190 4 mm thin bronchoscope
  • Device: BF-MP190F 3 mm ultrathin bronchoscope
  • Device: Radial ultrasound probe (UM S20-17S)
  • Device: PeriView FLEX 21G Single Use Aspiration Needle
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Evaluation of Thin and Ultrathin Bronchoscopy With Transbronchial Needle Aspiration and Radial Probe Endobronchial Ultrasound for Peripheral Pulmonary Lesions
Actual Study Start Date :
Apr 20, 2020
Anticipated Primary Completion Date :
Apr 30, 2024
Anticipated Study Completion Date :
Apr 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Bronchoscopy

Following airway inspection, the radial endobronchial ultrasound probe will be inserted through the working channel of the 4mm bronchoscope and will be advanced into the targeted bronchial segment towards the targeted lesion. Bronchoscopy will be performed using monoplanar fluoroscopic guidance until the peripheral lesion is located and confirmed using radial probe EBUS. a. If a concentric view is obtained, biopsy will proceed using conventional instruments (TBNA) through the 4mm bronchoscope. b. If an eccentric view is obtained, the 4mm bronchoscope will be withdrawn and the 3mm bronchoscope with the radial ultrasound probe will be advanced to the target lesion. Attempts will be made using the 3mm bronchoscope to obtain concentric views and ability to do so will be recorded. Biopsies will be obtained using conventional instruments (TBNA)through the 3mm bronchoscope regardless of the final ultrasound image (concentric or eccentric).

Device: BF-P190 4 mm thin bronchoscope
EVIS EXERA III Bronchofiberviedoscopes Olympus

Device: BF-MP190F 3 mm ultrathin bronchoscope
EVIS EXERA III Bronchofiberviedoscopes Olympus

Device: Radial ultrasound probe (UM S20-17S)
-Olympus

Device: PeriView FLEX 21G Single Use Aspiration Needle
NA-403D-2021 Gyrus ACMI, Inc.

Outcome Measures

Primary Outcome Measures

  1. Overall diagnostic yield (concentric and eccentric lesions) for peripheral pulmonary nodules [Receipt of cytology/histopathology results (approximately 7 days)]

    -To detect a 15% improvement in overall diagnostic yield (concentric and eccentric lesions) for peripheral pulmonary nodules utilizing using a combined approach of 4mm thin and 3mm ultrathin bronchoscopes with TBNA and radial EBUS compared to a historic baseline diagnostic yield of 60% established at Washington University School of Medicine (WUSM) when using TBNA and radial EBUS and a 4mm thin bronchoscope.

Secondary Outcome Measures

  1. Incidence of related adverse events [Up to 4 days following procedure]

    -Adverse events related to the bronchoscopy procedure and/or devices used during the procedure (bronchoscope, radial EBUS, PeriView Flex needle).

  2. Procedure time measured in minutes from oral scope insertion to scope removal upon completion of the bronchoscopy procedure [From start of procedure through end of procedure (day 1)]

  3. Size of target lesions measured at the greatest diameter in centimeters [From start of procedure through end of procedure (day 1)]

  4. Diagnostic yield of bronchoscopy utilizing a 3mm bronchoscope for eccentric lesions [Receipt of cytology/histopathology results (approximately 7 days)]

    -Will be compared with historical controlled data of cases in which peripheral bronchoscopy was performed for peripheral lesions using radial probe EBUS and a 4mm bronchoscope in which eccentric ultrasound views were obtained

  5. Ability to successfully convert ultrasound images from eccentric to concentric view by exchanging the 4mm thin bronchoscope for the 3mm ultrathin bronchoscope [From start of procedure through end of procedure (day 1)]

    -The ability to convert will be based on the ultrasound image that is obtained using the 3mm bronchoscope (it will either be eccentric or concentric) compared to the eccentric ultrasound image obtained with the 4mm bronchoscope

  6. Types of deficiencies associated with medical device [From start of procedure through end of procedure (day 1)]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients age 18 and older

  • Patients presenting with peripheral pulmonary lesions 1-7cm in greatest diameter on axial CT or PET scan in need of bronchoscopic biopsy for clinical purposes

Exclusion Criteria:
  • Patients who are unable to undergo flexible bronchoscopy as determined by the bronchoscopist prior to the procedure

  • Patients unwilling or unable to provide informed consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Washington University School of Medicine Saint Louis Missouri United States 63110

Sponsors and Collaborators

  • Washington University School of Medicine
  • Olympus

Investigators

  • Principal Investigator: Alexander Chen, M.D., Washington University School of Medicine

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT04331587
Other Study ID Numbers:
  • 202003071
First Posted:
Apr 2, 2020
Last Update Posted:
Jan 19, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 19, 2022